BioCardia Starts CardiAMP HF II Patient Enrollment at Emory
BioCardia announced that Emory University School of Medicine is enrolling patients in the Phase III CardiAMP HF II trial,...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trial Quality Clinical Trials CLINOPS WATCHDOG CNS Trials Conference Coverage CRO Consolidation Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
BioCardia announced that Emory University School of Medicine is enrolling patients in the Phase III CardiAMP HF II trial,...
ImPact Biotech will present updated preliminary results from its Phase 3 ENLIGHTED study of Padeliporfin VTP in patients with...
Verve Therapeutics has received FDA Fast Track designation for VERVE-102, a gene editing medicine designed as a single-course treatment...
Vantage Biosciences has initiated a Phase 2 clinical trial of VX-01, an oral therapy for non-proliferative diabetic retinopathy (NPDR)....
Folia Health has launched an at-home study for individuals with C3 glomerulopathy (C3G) in partnership with Novartis. The study...
Albatroz Therapeutics announced research published in •Nature Communications• demonstrating a novel therapeutic approach for arthritis using anti-Calnexin antibodies. The...
Clearmind Medicine Inc. has launched a Phase I/IIa clinical trial for its novel Alcohol Use Disorder (AUD) treatment, CMND-100,...
Theriva Biologics announced the presentation of interim safety and pharmacokinetic data from its ongoing Phase 1b/2a clinical trial of...
Unicycive Therapeutics announced positive patient-reported outcomes from a Phase 2 trial of its oxylanthanum carbonate (OLC) drug for hyperphosphatemia...
BriaPro Therapeutics, a majority-owned subsidiary of BriaCell Therapeutics, is developing novel, high-affinity antibodies targeting B7-H3, a molecule implicated in...